Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $37.8 million.

  • Connect Biopharma Holdings' Cash & Equivalents changed N/A to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year change of. This contributed to the annual value of $78.2 million for FY2024, which is 2596.08% down from last year.
  • Connect Biopharma Holdings' Cash & Equivalents amounted to $37.8 million in Q3 2025.
  • In the past 5 years, Connect Biopharma Holdings' Cash & Equivalents registered a high of $110.2 million during Q2 2024, and its lowest value of $37.8 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $71.7 million, with a median of $78.2 million in 2024.
  • In the last 5 years, Connect Biopharma Holdings' Cash & Equivalents skyrocketed by 3500.23% in 2024 and then tumbled by 6312.02% in 2025.
  • Connect Biopharma Holdings' Cash & Equivalents (Quarter) stood at $105.7 million in 2023, then decreased by 25.96% to $78.2 million in 2024, then plummeted by 51.62% to $37.8 million in 2025.
  • Its Cash & Equivalents was $37.8 million in Q3 2025, compared to $40.6 million in Q2 2025 and $47.7 million in Q1 2025.